ニューアムステルダム・ファーマ・カンパニー【NAMS】の掲示板

2026 Expected (Summary)

Regulatory / Commercial
• EMA approval expected in 2H 2026 for:
1. Obicetrapib  
2. Obicetrapib/ezetimibe fixed‑dose combination
• Partnership with "Menarini"

Financial Outlook Cash
sufficient to:
• Fund operations through the PREVAIL study readout
• Support a subsequent U.S. commercial launch, if approved

cf. copetitor（Merck）
MK-0616（Oral PCSK9 Inhibitor）
Phase3（NCT05952856）　
Study Completion 2025-07-28
Enrollment 2912

OLE study（NCT06492291）
Study Completion 2028-10-13＊
Enrollment 3000＊

CVOT study（NCT06008756）
Study Completion 2029-11-29＊
Enrollment 14550＊
＊ Estimated